Quarterly and annual results disclosed under 8-K Item 2.02.
Xenetic Biosciences, Inc. reported first quarter of 2024 results: net income Net loss for the quarter ended March 31, 2024 was approximately $1.2 million..
“On May 10, 2024, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended March 31, 2024 and providing a business update.”
AMC Global Media Inc. reported the first quarter ended March 31, 2024 results: revenue $596 million, EPS $1.03.
“of $151 million; Free Cash Flow (1) of $144 million. • Operating income of $110 million; Adjusted Operating Income (1) of $149 million, with a margin of 25%. • Net revenues of $596 million decreased 17% from the prior year. Excluding nonrecurring revenues related to Silo and 25/7 Media, net revenues decreased 6%. ◦ Streaming revenues of $145 million increased 3%”
Ubiquiti Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $493.0 million, net income $76.3 million, EPS $1.26.
“UBIQUITI INC. REPORTS THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS ~ Revenues of $493.0 million ~ ~ GAAP Diluted Earnings Per Share of $1.26 ~”
PhenixFIN Corp reported financial results for quarter ended March 31, 2024.
“PhenixFIN Corporation issued a press release announcing its financial results for the quarter ended March 31, 2024”
SOLENO THERAPEUTICS INC reported first quarter ended March 31, 2024 results: net income Net loss was approximately $21.4 million, or $0.59 per basic and diluted share, EPS $0.59 per basic and diluted share.
“Net loss was approximately $21.4 million, or $0.59 per basic and diluted share, for the quarter ended March 31, 2024”
SANUWAVE Health, Inc. reported first quarter ended March 31, 2024 results: revenue $5.8 million, net income $4.5 million. Guidance reaffirmed.
“in such filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 ef20028815_99-1.htm EXHIBIT 99.1 Exhibit 99.1 SANUWAVE Announces Q1 FY2024 Financial Results Q1 2024 revenues were $5.8 million, up 53% from Q1 2023 Q1 2024 gross margin was 73%, up 600bp from Q1 2023 Operating loss was $1.1 million for Q1 2024 compared to $2.0 million for Q1 2023 Company provides”
First Guaranty Bancshares, Inc. reported financial results for First Quarter 2024.
“On May 10, 2024 First Guaranty Bancshares, Inc. released its First Quarter 2024 Report to shareholders. The Press Release is enclosed as Exhibit 99.1 to this report.”
Neurogene Inc. reported financial results for the quarter ended March 31, 2024.
“On May 10, 2024, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2024.”
KIORA PHARMACEUTICALS INC reported the quarter ended March 31, 2024 results: revenue $16.0 million, net income $13.5 million.
“Revenue was $16.0 million for the first quarter of 2024, compared to no revenue in the first quarter of 2023. The revenue comes from collaboration revenue as part of an upfront payment from TOI connected to the strategic development and commercialization partnership. Research and development expenses were $1.5 million, net of $0.2 million in offsetting credits related to expenses for KIO-301 which will be reimbursed by TOI, for the first quarter of 2024, compared to $0.4 million, net of $0.3 million in offsetting tax credits, for the first quarter of 2023. The increase was primarily due to a one-time licensing payment made to the University of California related to a sublicense fee of $0.7 million, and a decrease of $0.3 million in R&D tax credits due to reduced credit-eligible expenses given the KIO-301 expenses are now being reimbursed by TOI. General and administrative expenses were $1.3 million for the first quarter of 2024, compared to $1.3 million for the first quarter of 2023. N”
Calumet Specialty Products Partners, L.P. reported first quarter ended March 31, 2024 results: net income $(41.6) million, EPS $(0.51) basic net loss per unit.
“On May 10, 2024, Calumet Specialty Products Partners, L.P. reported results of operations for the quarter ended March 31, 2024, pursuant to a press release.”
FutureFuel Corp. reported financial results for first quarter ended March 31, 2024.
“On May 10, 2024, FutureFuel Corp. (NYSE: FF) (the “Company”) issued a press release announcing its financial and operating results for the first quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report.”
Opus Genetics, Inc. reported first quarter ended March 31, 2024 results: revenue $1.7 million, net income $7.1 million, EPS ($0.29).
“Financial Highlights for the First Quarter Ended March 31, 2024 As of March 31, 2024, Ocuphire had cash and cash equivalents of $47.2 million. Based on current projections, management believes that the cash on hand will be sufficient to fund operations into mid-2025. License and collaborations revenue was $1.7 million for first quarter ending March 31, 2024 compared with $1.7 million in the first quarter of 2023. Revenue during both quarterly periods was derived from the Viatris license agreement largely for the reimbursement of research and development services. During the first quarter of 2024 Ocuphire earned its first royalty payment in the amount of $3,000 stemming from the sale of RYZUMVI by Viatris in late March 2024. General and administrative expenses for the first quarter ended March 31, 2024 were $4.7 million , compared to $2.3 million for first quarter of 2023. The increase period over period was primarily attributable to increases in payroll related costs, stock-based compe”
Star Equity Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $33.9 million, net income Net loss was $2.9 million, or $0.95 per diluted share.
“Company"), a leading global total talent solutions company, announced today financial results for the first quarter ended March 31, 2024. 2024 First Quarter Summary • Revenue of $33.9 million decreased 21.3% from the first quarter of 2023 and 20.1% in constant currency. • Adjusted net revenue of $16.3 million decreased 25.0% from the first quarter of 2023 and 24.6% in”
TruBridge, Inc. reported first quarter ended March 31, 2024 results: revenue $83.2 million, EPS $(0.17). Guidance reaffirmed.
“Quarter 2024 Highlights All comparisons are to the quarter ended March 31, 2023, unless otherwise noted ● Bookings of $23.6 million compared to $19.8 million ● Total revenue of $83.2 million compared to $86.2 million ● Revenue Cycle Management (RCM) revenue of $53.0 million compared to $48.6 million o RCM revenue represented 63.7% of TruBridge’s total revenue ● GAAP”
CUTERA INC reported financial results for three and twelve months ended December 31, 2023.
“The Original Form 8-K included, as Exhibit 99.1, a copy of the Company’s earnings press release issued on March 21, 2024 (the “Earnings Release”), which included, the Company’s consolidated financial statements and certain non-GAAP measures for the three and twelve months ended December 31, 2023 and 2022.”
CBAK Energy Technology, Inc. reported financial results for the first quarter ended March 31, 2024.
“On May 10, 2024, CBAK Energy Technology, Inc. (the “Company”) released its unaudited results of operations for the first quarter ended March 31, 2024.”
INNOSPEC INC. reported first quarter ended March 31, 2024 results: revenue $500.2 million, net income $41.4 million, EPS $1.65 per diluted share.
“Total revenues for the first quarter were $500.2 million, a decrease of 2 percent from $509.6 million in the corresponding period last year. Net income for the quarter was $41.4 million or $1.65 per diluted share compared to $33.2 million or $1.33 per diluted share recorded in the corresponding period last year.”
NATIONAL HEALTHCARE CORP reported the quarter ended March 31, 2024 results: revenue $297,176,000, net income $26,213,000, EPS $1.69.
“(NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues for the quarter ended March 31, 2024 totaled $297,176,000 compared to $269,563,000 for the quarter ended March 31, 2023, an increase of 10.2%. For the quarter ended March 31, 2024, the reported GAAP net income attributable to NHC was”
SONIDA SENIOR LIVING, INC. reported financial results for first quarter ended March 31, 2024.
“On May 10, 2024, Sonida Senior Living, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024 by issuing a press release. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1.”
Global Self Storage, Inc. reported first quarter ended March 31, 2024 results: revenue Total revenues were unchanged at $3.0 million, net income Net income decreased to $266,000, EPS $0.02 per diluted share.
“results for the first quarter ended March 31, 2024. All comparisons are to the same year-ago period unless otherwise noted. Q1 2024 Highlights • Total revenues were unchanged at $3.0 million. • Net income decreased to $266,000 or $0.02 per diluted share from $993,000 or $0.09 per diluted share. • Funds from operations (FFO) decreased 18.3% to $0.8 million or $0.08”
INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2024 results: revenue $13.1 million, net income $0.3 million, EPS $0.01.
“(the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023 were approximately $13.1 million. The Company had operating income for the quarter ended March 31, 2024 and 2023 of approximately $0.4 million and $44,000, respectively. Revenue for the nine-month period ended”
ANI PHARMACEUTICALS INC reported the quarter ended March 31, 2024 results: revenue $137.4 million, net income $17.8 million, EPS $0.82. Guidance reaffirmed.
“ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance • Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82”
UNITED GUARDIAN INC reported first quarter of 2024 results: revenue $3,254,944, net income $925,442, EPS $0.20 per share.
“United-Guardian Reports Increased First Quarter Sales & Earnings HAUPPAUGE, N.Y., May 10, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2024. First quarter sales increased from $2,570,324 in 2023 to $3,254,944 in 2024, with net income increasing from $756,081 ($0.16 per share) to $925,442 ($0.20 per share).”
Protalix BioTherapeutics, Inc. reported financial results for the quarter ended March 31, 2024.
“Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.”
ALTABA INC. reported financial results for the quarter ended March 31, 2024.
“On May 10, 2024, Altaba Inc., a Delaware corporation, published its unaudited consolidated statement of assets and liabilities for the quarter ended March 31, 2024.”
NOVAVAX INC reported the first quarter ended March 31, 2024 results: revenue $94 million.
“half of 2024, with potential 2026 launch for both candidates · Reduced current liabilities by an additional $831 million during Q1 2024 · Achieved total revenue in Q1 2024 of $94 million · Novavax removes going concern notice · Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md., May 10, 2024 – Novavax, Inc. (Nasdaq: NVAX), a global company”
Vertex Energy Inc. reported the first quarter of 2024 results: net income ($17.7) million, or ($0.19) per fully-diluted share, EPS ($0.19) per fully-diluted share.
“Vertex Energy, Inc. (NASDAQ:VTNR) (“Vertex” or the “Company”), a leading specialty refiner and marketer of high-quality refined products and renewable fuels, today announced its operational and financial results for the first quarter of 2024.”
CANTALOUPE, INC. reported third quarter ended March 31, 2024 results: revenue $67.9 million, net income $4.4 million, EPS $0.06 per share.
“Cantaloupe, Inc. Reports Third Quarter Fiscal Year 2024 Financial Results Third Quarter 2024 Revenue of $67.9 Million, Driven by 15.5% Year Over Year Growth in Subscription and Transaction Fees Third Quarter 2024 Net Income Applicable to Common Shares of $4.4 Million and Adjusted EBITDA of $10.2 Million”
PAPA JOHNS INTERNATIONAL INC reported first quarter ended March 31, 2024 results: revenue $514 million, EPS $0.44.
“Highlights • North America comparable sales (a) were down 2% from a year ago as Domestic Company-owned restaurants were down 3% and North America franchised restaurants were down 2%; International comparable sales (a) were down 3% from the prior year period. • 8 net unit openings in the first quarter driven by North America growth; on track to achieve North America net unit growth of more than 20% relative to 2023 net unit openings and International gross openings between 100 and 140 new restaurants. • Global system-wide restaurant sales were $1.23 billion, a 1% (b) decrease compared with the prior year first quarter due entirely to the 53rd week in 2023 which shifted the week between Christmas and New Years into the fourth quarter. • Total revenues of $514 million were down 2% compared with a year ago largely driven by lower revenues in our North America commissary segment due to commodity price declines. • Operating income of $34 million decreased 11% compared with the first quarter”
SIFCO INDUSTRIES INC reported second quarter of fiscal 2024, which ended March 31, 2024 results: revenue $26.5 million, net income $(1.6) million, EPS $(0.26) per diluted share.
“SIFCO Industries, Inc. (NYSE American: SIF) today announced financial results for its second quarter of fiscal 2024, which ended March 31, 2024. Second Quarter Results • Net sales in the second quarter of fiscal 2024 increased 37.9% to $26.5 million, compared with $19.2 million for the same period in fiscal 2023. • Net loss for the second quarter of fiscal 2024 was $(1.6) million, or $(0.26) per diluted share, compared with net loss of $(2.4) million, or $(0.40) per diluted share, in the second quarter of fiscal 2023.”
NEKTAR THERAPEUTICS reported first quarter ended March 31, 2024 results: revenue $21.6 million, net income $36.8 million or $0.19 basic and diluted loss per share, EPS $0.19 basic and diluted loss per share.
“the TNFR2 receptor is progressing through IND-enabling studies to support entering the clinic next year.” Summary of Financial Results Revenue in the first quarter of 2024 was $21.6 million as compared to the same $21.6 million in the first quarter of 2023. Total operating costs and expenses in the first quarter of 2024 were $57.1 million as compared to $156.3”
CENTURY CASINOS INC /CO/ reported the three months ended March 31, 2024 results: revenue $136.0 million, net income ($13.5) million, EPS ($0.45).
“financial results for the three months ended March 31, 2024 . F irst Quarter 202 4 Highlights* Compared to the three months ended March 31, 2023 : · Net operating revenue was $136.0 million, an increase of 25%. · Earnings from operations were $8.3 million, a decrease of (55%). · Net loss attributable to Century Casinos, Inc. shareholders was ($13.5) million, a”
FORWARD AIR CORP reported three months ended March 31, 2024 results: revenue $541,813, net income $(88,794), EPS $(2.35).
“synergies are fully realized by the end of 2025.” Three Months Ended (in thousands, except per share data) March 31, 2024 March 31, 2023 Change Percent Change Operating revenue $ 541,813 $ 357,709 $ 184,104 51.5 % (Loss) income from operations $ (65,732) $ 47,196 $ (112,928) (239.3) % Operating margin (12.1) % 13.2 % (2,530) bps Net (loss) income $ (88,794) $”
ENGLOBAL CORP reported the three-months ended March 30, 2024 results: revenue $6.5 million, net income Net loss in the quarter was $1.4 million, EPS $0.27 per fully diluted share.
“are on a path to profitability through improved operating efficiencies and a commitment to enhanced project execution.” Revenues for the three months ended March 30, 2024 were $6.5 million compared to $13.2 million for the same period in 2023. Net loss in the quarter was $1.4 million, compared to a net loss of $6.3 million in the same quarter a year ago. ENGlobal”
ACACIA RESEARCH CORP reported quarter ended March 31, 2024 results: revenue 24.3, net income -0.2, EPS 0.00.
“data) Three Months Ended March 31, 2024 2023 (unaudited) Intellectual property operations $ 13.6 $ 4.2 Industrial operations 8.8 10.6 Energy operations 1.9 — Total revenues $ 24.3 $ 14.8 Operating loss $ (2.1) $ (9.3) Unrealized (losses) gains 1 $ (26.7) $ 3.3 Realized gains (losses) $ 28.9 $ (1.4) Legal liability fee $ (6.2) $ — Non-cash derivative”
RCI HOSPITALITY HOLDINGS, INC. reported fiscal 2024 second quarter ended March 31, 2024 results: revenue $72.3, net income $0.8, EPS $0.08.
“the fiscal 2024 second quarter ended March 31, 2024. The company also filed its Form 10-Q today. Summary Financials (in millions except EPS) 2Q24 2Q23 6M24 6M23 Total revenues $72.3 $71.5 $146.2 $141.5 EPS $0.08 $0.83 $0.85 $1.94 Non-GAAP EPS 1 $0.90 $1.30 $1.76 $2.50 Other charges, net $8.2 $3.8 $8.2 $3.1 Net cash from operating activities $10.8 $16.8 $24.5”
ACHIEVE LIFE SCIENCES, INC. reported financial results for first quarter ended March 31, 2024.
“On May 9, 2024, Achieve Life Sciences, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
INCOME OPPORTUNITY REALTY INVESTORS INC /TX/ reported the quarter ended March 31, 2024 results: net income $1.2 million, EPS $0.29 per diluted share.
“For the three months ended March 31, 2024, we reported net income attributable to common shares of $1.2 million or $0.29 per diluted share compared to a net income of $1.1 million or $0.25 per share for the same period in 2023.”
Primo Water Corp /CN/ reported the first quarter ended March 30, 2024 results: revenue $452 million, net income $19 million, EPS $0.12 per diluted share. Guidance raised.
“Revenue increased 9.6% to $452 million compared to $413 million driven by revenue growth consisting of 5.1% volume and 4.5% pricing. Organic growth was 8.3% for the quarter. Revenue growth by channel includes 9% in Water Direct / Water Exchange, 11% in Water Refill / Water Filtration and 57% in Other Water, which is primarily Mountain Valley Spring water sold at retail. 1 • Gross profit increased 12% to $291 million compared to $259 million. Gross margin increased 160 bps to 64.4% compared to 62.8%, driven by pricing initiatives, increased volume and operating efficiencies. • SG&A expenses increased 6% to $249 million compared to $235 million. The increase was driven by higher selling and operating costs including delivery commissions that supported volume and revenue growth. • Reported net income and net income per diluted share were $19 million and $0.12, respectively, compared to reported net income and net income per diluted share of $3 million and $0.02, respectively. Adjusted net”
LIGHTPATH TECHNOLOGIES INC reported the fiscal 2024 third quarter ended March 31, 2024 results: revenue $7.6 million, net income $2.6 million.
“Revenue of $7.6 million for the third quarter of fiscal 2024 - 18% of revenue was for customized lens assemblies and solutions and related engineering services, or LightPath 2.0 as we refer to these product groups · Total backlog at March 31, 2024 of $22.0 million · Net loss for the third quarter of fiscal 2024 was $2.6 million”
SAGA COMMUNICATIONS INC reported quarter ended March 31, 2024 results: revenue $24.7 million, net income net loss of $1.6 million, EPS $0.25.
“net revenue decreased 2.5% to $24.7 million for the quarter ended March 31, 2024”
ARROWHEAD PHARMACEUTICALS, INC. reported Fiscal 2024 second quarter (three months ended March 31, 2024) results: net income Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. $ (125,300), EPS Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted $ (1.02).
“OPERATING SUMMARY 2024 2023 (Unaudited) Revenue $ — $ 146,267 Operating Expenses: Research and development 101,122 74,881 General and administrative expenses 25,069 23,221 Total Operating Expenses 126,191 98,102 Operating (loss) income (126,191) 48,165 Total other expense (805) (489) (Loss) income before income tax expense and noncontrolling interest (126,996) 47,676 Income tax expense — — Net (loss) income including noncontrolling interest (126,996) 47,676 Net (loss) income attributable to noncontrolling interest, net of tax (1,696) (999) Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. $ (125,300) $ 48,675 Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted $ (1.02) $ 0.45”
ACORN ENERGY, INC. reported financial results for first quarter ended March 31, 2024 (Q1'24).
“On May 9, 2024, the Registrant issued a press release announcing its 2024 first quarter results.”
Lineage Cell Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $1.4 million.
“Total revenues for the three months ended March 31, 2024 were approximately $1.4 million”
LIFETIME BRANDS, INC reported first quarter ended March 31, 2024 results: revenue $142.2 million, net income $(6.3) million, or $(0.29) per diluted share, EPS $(0.29) per diluted share.
“Consolidated net sales for the three months ended March 31, 2024 were $142.2 million, representing a decrease of $3.2 million, or 2.2%, as compared to net sales of $145.4 million for the corresponding period in 2023.”
ProPhase Labs, Inc. reported financial results for the three months ended March 31, 2024.
“ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
ProPhase Labs, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 9, 2024, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
ESCO TECHNOLOGIES INC reported full year fiscal 2024 results: revenue $1.02 to $1.04 billion, EPS $4.15 to $4.30. Guidance reaffirmed.
“full year adjusted earnings per share guidance is being maintained in the range of $4.15 to $4.30 (12 to 16 percent growth). This represents ESCO’s third year in a row of double-digit earnings growth. This outlook is based on sales in line with our initial guidance range of $1.02 to $1.04 billion (7 to 9 percent annual growth).”
ESCO TECHNOLOGIES INC reported Q2 2024 results: revenue $249.1 million, EPS $0.90 per share.
“ESCO REPORTS SECOND QUARTER FISCAL 2024 RESULTS - Q2 Sales increase 9% to $249 Million - - Q2 GAAP EPS increases 30% to $0.90 - - Q2 Adjusted EPS increases 24% to $0.94”
ALLEGRO MICROSYSTEMS, INC. reported financial results for quarter and fiscal year ended March 29, 2024.
“On May 9, 2024, Allegro MicroSystems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended March 29, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.